NRAS Mutation
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma (NCT07750067) | Sun Yat-sen University | 2026-04-01 |
| A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors (NCT07584226) | Relay Therapeutics, Inc. | 2026-03-09 |
Track NRAS Mutation automatically
Every clearance here is in the API, with alerts when new ones post.